Susan A. Melin, M.D.Wake Forest Baptist Health

Doctor Rating

4.6 out of 5

137 Ratings

Susan A. Melin, M.D.


Clinical Interests

Breast Cancer

Contact Information

New Patient Appointments: 336-716-WAKE
Returning Patient Appointments: 336-713-5440
Department: 336-716-4464

Insurance Accepted »

Education & Training

  • B.S., University of North Carolina-Chapel Hill, 1977
  • M.D., WFU School of Medicine, 1985
  • Residency, Eastern Virginia Med School, 1988
  • Fellowship, Univ of NC at Chapel Hill, 1991

Board Certifications

  • American Board of Internal Medicine, Hematology
  • American Board of Internal Medicine, Internal Medicine
  • American Board of Internal Medicine, Medical Oncology


  • North Carolina Medical Society
  • Am Coll Of Physicians
  • Am Medical Assn
  • Am Soc of Clinical Oncology

NPI Number

  • 1528042058
Susan A. Melin, M.D.

Doctor Rating

4.6 out of 5

137 Ratings

Susan A. Melin, M.D.

Professor, Hematology & Oncology

Research Interests

cancer/oncogenesis, drugs/therapeutic agents pharm, women's health issues

Contact Information

Academic: 336-716-7975 | Department: 336-716-4464

Recent Publications

Cowherd S, Miller LD, Melin SA, Akman S, Isom S, Cole J, Pullikuth A, Lawrence JA. A phase II clinical trial of weekly paclitaxel and carboplatin in combination with panitumumab in metastatic triple negative breast cancer. Cancer Biol Ther. 2015;16(5):678-683.

Vitolins MZ, Milliron BJ, Hopkins JO, Fulmer A, Lawrence J, Melin S, Case D. Weight loss intervention in survivors of ER/PR-negative breast cancer. Clin Med Insights Womens Health. 2014;7():17-24.

Ahmed S, Lawrence J, Stewart JH, Melin S, Levine EA, Howard-McNatt M. Does age predict outcome in patients with inflammatory breast cancer?. Am Surg. 2014;80(8):E221-E224.

Cowherd S, Melin S, Akman S, Cole J, Lawrence J. A phase II clinical trial of weekly paclitaxel and carboplatin in combination with panitumumab in metastatic or recurrent breast cancer patients with triple negative disease [abstract]. Cancer Res. 2014;74(19 Suppl):CT302.

Howard-McNatt M, Lawrence J, Melin SA, Levine EA, Shen P, Stewart JH IV. Race and recurrence in women who undergo neoadjuvant chemotherapy for breast cancer. Am J Surg. 2013;205(4):397-401.

Rugo HS, Serrurier K, Melisko M, Glencer A, Hwang J, D'Agostino R, Hutchens S, Esserman L, Melin S. The Dignicap System to prevent alopecia in women receiving chemotherapy for breast cancer [abstract]. Breast. 2013;22(Suppl 1):S119.

Lawrence JA, Akman SA, Melin SA, Case LD, Schwartz GG. Oral paricalcitol (19-nor-1,25-dihydroxyvitamin D2) in women receiving chemotherapy for metastatic breast cancer: a feasibility trial. Cancer Biol Ther. 2013;14(6):476-480.

Drafts BC, Twomley KM, D'Agostino R Jr, Lawrence J, Avis N, Ellis LR, Thohan V, Jordan J, Melin SA, Torti FM, Little WC, Hamilton CA, Hundley WG. Low to moderate dose anthracycline-based chemotherapy is associated with early noninvasive imaging evidence of subclinical cardiovascular disease. JACC Cardiovasc Imaging. 2013;6(8):877-885.

Chaosuwannakit N, D'Agostino R Jr, Hamilton CA, Lane KS, Ntim WO, Lawrence J, Melin SA, Ellis LR, Torti FM, Little WC, Hundley WG. Aortic stiffness increases upon receipt of anthracycline chemotherapy. J Clin Oncol. 2010;28(1):166-172.

Vitolins M, Lesser GJ, Case LD, Williford SK, Giguere JK, Garino A, Naughton MJ, Lively M, Melin SA, Shaw EG. Self-reported compliance compared to biomarker levels of vitamin E in breast cancer patients participating in a CoQ10 clinical trial [abstract]. J Clin Oncol. 2010;28(15 Suppl):e19524.

Twomley K, D'Agostino R Jr, Lawrence J, Melin S, Ellis LR, Stacey B, Hamilton CA, Torti F, Little W, Hundley W. Early and persistent evidence of subclinical cardiovascular injury after receipt of anthracycline chemotherapy [abstract]. Circulation. 2010;122(21 Suppl):A12766.

Chaosuwannakit N, D'Agostino R Jr, Hamilton CA, Lane KS, Ntim WO, Lawrence J, Melin SA, Ellis LR, Torti FM, Little WC, Hundley WG. Subclinical cardiovascular toxicity of anthracyclines identified with cardiovascular magnetic resonance imaging [abstract]. Circulation. 2009;120(18 Suppl):S299.

Ramanathan RK, Picus J, Raftopoulos H, Bernard S, Lockhart AC, Frenette G, Macdonald J, Melin S, Berg D, Brescia F, et al. A phase II study of milataxel: a novel taxane analogue in previously treated patients with advanced colorectal cancer. Cancer Chemother Pharmacol. 2008;61(3):453-458.

Miller AA, Case D, Harmon M, Savage P, Lesser G, Hurd D, Melin SA. Phase I study of lenalidomide in solid tumors. J Thorac Oncol. 2007;2(5):445-449.

Kim C, Farmer MR, Yacoub J, Monjazeb A, Levine EA, Aklilu M, Geinsinger [sic] KR [Geisinger KR], Mishra G, Melin S, Blackstock AW. Tri-modality therapy for esophageal cancer: mucinous histology is associated with decreased pathologic response rates to neoadjuvant chemoradiation therapy [abstract]. Int J Radiat Oncol Biol Phys. 2007;69(3 Suppl):S267.

Monjazeb AM, Farmer MR, Mattern M, Mebea A, Levine EA, Geisinger KR, Mishra G, Melin S, Blackstock AW. Patterns of failure for esophageal cancer patients optimally staged with 18-F-FDG-PET and observed after chemo-radiotherapy [abstract]. Int J Radiat Oncol Biol Phys. 2007;69(3 Suppl):S274.

Blackstock AW, Mornex F, Partensky C, Descos L, Case LD, Melin SA, Levine EA, Mishra G, Limentani SA, Kachnic LA, et al. Adjuvant gemcitabine and concurrent radiation for patients with resected pancreatic cancer: a phase II study. Br J Cancer. 2006;95(3):260-265.

Blackstock AW, Aklilu M, Lovato J, Farmer MR, Mishra G, Melin SA, Oaks T, Geisinger K, Levine EA. Pathologic complete response may not represent the optimal surrogate for survival after preoperative therapy for esophageal cancer. Int J Gastrointest Cancer. 2006;37(1):7-14.

Farmer MR, Yacoub J, Aklilu M, Levine EA, Geisinger K, Mishra G, Melin S, Blackstock AW. Tri-modality therapy for esophageal cancer: hemoglobin levels are prognostic for survival but do not predict response to radiochemotherapy [abstract]. Int J Radiat Oncol Biol Phys. 2006;66(3 Suppl):S269.

All Publications

For a listing of recent publications, refer to PubMed, a service provided by the National Library of Medicine.

For a list of earlier publications, visit the Carpenter Library Publication Search.

Professor, Hematology & Oncology

Clinical Interests

Breast Cancer
Susan A. Melin, M.D.

Susan A. Melin, M.D.

Professor, Hematology & Oncology

Doctor Rating

4.6 out of 5

Susan A. Melin, M.D.137 Ratings


Doctor Ratings

The overall Patient Rating score is the average of responses to the nine questions listed below. The questions are from the Press Ganey Patient Satisfaction Survey. Responses are measured on a 1 to 5 scale, where 1 represents "very poor" and 5 represents "very good."
Press Ganey Patient Satisfaction Survey

CP concern for questions/worries
CP efforts to include in decisions
CP explanations of prob/condition
CP spoke using clear language
Friendliness/courtesy of CP
Likelihood of recommending CP
Patients' confidence in CP
Time CP spent with patient
Wait time at clinic

Patient Comments

Comments are taken from the Care Provider section of the Press Ganey Patient Satisfaction Survey. Comments are posted exactly as they are written. Comments are added weekly. To protect patient privacy and confidentiality, patient names are not included.


Everyone is great.


I have great doctors, that show a lot of concern for my care..


My provider is great she always takes time to answer questions and she's very considerate she has a very good and sweet spirit and she's smart.????


waited too long and didn't spend much time with patient.


I have the utmost confidence in Dr. Melin.


Dr. Susan Melin has picked up on important health issues, unrelated to Oncology, on two occasions. She immediately ordered scans or tests related to the concerns. In both cases, the concerns were valid.


The only problem I have with Dr. Melin is the terriblly long time I have to wait after I'm put in an exam room!


Dr. Melin is a very caring and compassionate Dr. I feel very lucky to be under her care.


the care provided by Dr Melin and her staff has been excellent


I started off at Marshall University with a oncologist that I didn't care for. I was referred to Duke, where Dr. Kimmick sent me to Dr. Melin at Wake Forest to participate in a clinical trial. As soon as I got to Wake Forest Baptist, I knew I was home. This was my hospital and Dr. Melin was my doctor. No more bouncing around.


I did not feel rushed at all.


*Dr. Melin is an extraordinary oncologist who is both very competent & compassionate.

Quick Reference

Request an Appointment
New Patients


Existing patients may contact the clinic directly.
Find a Doctor Ways to Give
USNWR 2015-2016Magnet Hospital RecognitionConsumer Choice2015 Best DoctorsJoint Commission Report

Disclaimer: The information on this website is for general informational purposes only and SHOULD NOT be relied upon as a substitute for sound professional medical advice, evaluation or care from your physician or other qualified health care provider.